Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
NCT02992483
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Interventions
DRUG:
MIK665
Sponsor
Novartis Pharmaceuticals